Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
82 hedge funds and large institutions have $391M invested in Revance Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 18 reducing their positions, and 15 closing their positions.
219% more call options, than puts
Call options by funds: $855K | Put options by funds: $268K
89% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 18
5% less funds holding
Funds holding: 86 → 82 (-4)
18% less capital invested
Capital invested by funds: $475M → $391M (-$83.6M)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$12.1M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$9.46M |
| 3 |
JP Morgan Chase
New York
|
+$5.28M |
| 4 |
PC
PointState Capital
New York
|
+$4.42M |
| 5 |
Bank of New York Mellon
New York
|
+$2.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$2.87M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.05M |
| 3 |
JCG
JHL Capital Group
Chicago,
Illinois
|
-$1.92M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.73M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$1.65M |
RVNC Hedge Fund Activity: Q2 2016 in Review
82 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2016, worth a combined $391M — down 18% from $475M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of RVNC and 11 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 34 added.
The largest buyer was Wellington Management Group, adding an estimated $12.1M. The largest seller was Franklin Resources, cutting an estimated $2.87M.
- 82 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2016, down from 86 in Q1 2016.
- Funds reported $391M of Revance Therapeutics, Inc. stock for Q2 2016, down 18% quarter-over-quarter.
- 11 funds opened new Revance Therapeutics, Inc. positions in Q2 2016 and 15 closed out, a net change of -4 holders.
- The largest Revance Therapeutics, Inc. buyer in Q2 2016 was Wellington Management Group, an estimated $12.1M added.
- The largest Revance Therapeutics, Inc. seller in Q2 2016 was Franklin Resources, an estimated $2.87M sold.
Based on aggregated 13F filings for Q2 2016.